Australia TGA ARTG recordMedicine administration kit, percutaneous, medicated, single-use
Australia TGA ARTG Registered Device · Sanofi-Aventis Australia Pty Ltd · Ablynx NV · Class IIa · Started April 29, 2020
Good Name: Sanofi-Aventis Australia Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use
- Risk Class
- Class IIa
- Product Type
- Procedure Pack
- ARTG Category
- General
- Start Date
- April 29, 2020
- Effective Date
- April 29, 2020
- Name
- Ablynx NV
- Country
- Belgium
- Address
- Technologiepark 21, Zwijnaarde, 9052
Cablivi (AUST R 318058) is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. Each pack contains a caplacizumab powder vial and prefilled diluent syringe supplied together with a vial adapter, needle and swabs suitable for administration. Packs of 1x or 7x all components.
Access comprehensive regulatory information for Medicine administration kit, percutaneous, medicated, single-use in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIa is sponsored by Sanofi-Aventis Australia Pty Ltd, manufactured by Ablynx NV in Belgium. The device registration started on April 29, 2020.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.